(Q38019567)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22708597%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

Cortical interneurons, immune factors and oxidative stress as early targets for schizophrenia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22708597%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22708597%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

author name string

Patricio O'Donnell

series ordinal

1

1 reference

27 August 2017

language of work or name

English

0 references

publication date

1 June 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22708597%20AND%20SRC:MED&resulttype=core&format=json

European Journal of Neuroscience

5 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22708597%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22708597%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22708597%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

page(s)

1866-1870

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22708597%20AND%20SRC:MED&resulttype=core&format=json

Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial

5 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

The effect of extract of ginkgo biloba addition to olanzapine on therapeutic effect and antioxidant enzyme levels in patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Does schizophrenia arise from oxidative dysregulation of parvalbumin-interneurons in the developing cortex?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Ketamine-induced loss of phenotype of fast-spiking interneurons is mediated by NADPH-oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Interleukin-6 mediates the increase in NADPH-oxidase in the ketamine model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Postnatal NMDA receptor ablation in corticolimbic interneurons confers schizophrenia-like phenotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

N-acetyl cysteine as a glutathione precursor for schizophrenia--a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Prenatal immune challenge disrupts sensorimotor gating in adult rats. Implications for the etiopathogenesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Prenatal infection as a risk factor for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Exposure to prenatal infection and risk of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

The evolution of drug development in schizophrenia: past issues and future opportunities

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

The GABA-glutamate connection in schizophrenia: which is the proximate cause?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Human Neuroblasts Migrate to the Olfactory Bulb via a Lateral Ventricular Extension

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Redox dysregulation, neurodevelopment, and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

A placebo-controlled study of extract of ginkgo biloba added to clozapine in patients with treatment-resistant schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Safety of the omega-3 fatty acid, eicosapentaenoic acid (EPA) in psychiatric patients: results from a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Reducing prefrontal gamma-aminobutyric acid activity induces cognitive, behavioral, and dopaminergic abnormalities that resemble schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Neonatal intrahippocampal immune challenge alters dopamine modulation of prefrontal cortical interneurons in adult rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

A placebo-controlled trial of omega-3 fatty acid (ethyl eicosapentaenoic acid) supplementation for residual symptoms and cognitive impairment in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Developmental patterns of doublecortin expression and white matter neuron density in the postnatal primate prefrontal cortex and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Prefrontal lesion reverses abnormal mesoaccumbens response in an animal model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Neurogenesis in the neocortex of adult primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

More is less: a disinhibited prefrontal cortex impairs cognitive flexibility

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Glutamatergic neurotransmission modulators as emerging new drugs for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Dominant-negative DISC1 transgenic mice display schizophrenia-associated phenotypes detected by measures translatable to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Modulation of [3H]dopamine release by glutathione in mouse striatal slices

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Amelioration of negative symptoms in schizophrenia by glycine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Role of dysbindin in dopamine receptor trafficking and cortical GABA function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Neurodevelopmental damage after prenatal infection: role of oxidative stress in the fetal brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Glutathione precursor, N-acetyl-cysteine, improves mismatch negativity in schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Cognitive dysfunction in schizophrenia: convergence of gamma-aminobutyric acid and glutamate alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Cortical inhibitory neurons and schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Subunit-selective modulation of GABA type A receptor neurotransmission and cognition in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Excitotoxic lesions of the rat medial prefrontal cortex. Effects on abnormal behaviors associated with neonatal hippocampal damage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Gestational methylazoxymethanol acetate administration: a developmental disruption model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

A loss of parvalbumin-containing interneurons is associated with diminished oscillatory activity in an animal model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Prenatal and postnatal maternal contributions in the infection model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Differential laminar effects of amphetamine on prefrontal parvalbumin interneurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Knockdown of DISC1 by in utero gene transfer disturbs postnatal dopaminergic maturation in the frontal cortex and leads to adult behavioral deficits

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Adolescent onset of cortical disinhibition in schizophrenia: insights from animal models

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

A dose-ranging exploratory study of the effects of ethyl-eicosapentaenoate in patients with persistent schizophrenic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Decrease in parvalbumin-expressing neurons in the hippocampus and increased phencyclidine-induced locomotor activity in the rat methylazoxymethanol (MAM) model of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Glutamate receptor subtypes mediating synaptic activation of prefrontal cortex neurons: relevance for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Dopamine receptors and the dopamine hypothesis of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Dopamine modulation of prefrontal cortical interneurons changes during adolescence

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Altered prefrontal cortical metabolic response to mesocortical activation in adult animals with a neonatal ventral hippocampal lesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

A neonatal ventral hippocampal lesion causes functional deficits in adult prefrontal cortical interneurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

Altered glutathione redox state in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

The effect of extract of ginkgo biloba added to haloperidol on superoxide dismutase in inpatients with chronic schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X

What are the functional consequences of neurocognitive deficits in schizophrenia?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1460-9568.2012.08130.X